LONA — LeonaBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1620463 ·
Last close
$2.76
Market Cap
$26.00M
52W High
$14.21
52W Low
$2.21
ADV30
77,621
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -21,878,000 | -21,164,000 | 38,136,000 | 16,336,000 | 22,119,000 |
| Jun 2026 | 0 | — | -19,278,000 | -19,007,000 | 56,894,000 | 32,323,000 | 23,299,000 |
| Mar 2026 | 0 | — | -18,143,000 | -32,948,000 | 71,590,000 | 32,833,000 | 22,287,000 |
| Dec 2025 | 0 | — | -10,477,000 | -82,889,000 | 92,151,000 | 69,276,000 | 64,361,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-61,926,000
Investing CF
$-8,190,000
Financing CF
$82,437,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.99
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-563,710,000
Inventory
—
Receivables
—
ST Investments
$18,744,000
EBIT TTM
$-54,772,000
Pretax Income TTM
$-141,455,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,178,000 | -105,609,000 | 92,151,000 | 64,361,000 | 27,790,000 | -45,729,000 |
| Dec 2024 | 0 | -96,775,000 | -96,940,000 | 58,779,000 | 13,938,000 | 44,841,000 | -97,170,000 |
| Dec 2023 | 0 | -126,937,000 | -117,672,000 | 160,245,000 | 30,057,000 | 130,188,000 | -100,753,000 |
| Dec 2022 | 0 | -88,855,000 | -95,639,000 | 258,153,000 | 23,016,000 | 235,137,000 | -72,469,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$60,859,000
NetIncome TTM
$-141,455,000
OpCashFlow TTM
—
Assets (Latest)
$56,894,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTHS | Pelthos Therapeutics Inc. | $26.89M | $6.84 | — |
| EVAX | Evaxion A/S | $25.08M | $2.78 | — |
| SAEN | Genenta Science S.p.A. | $27.82M | $0.58 | — |
| MGX | Metagenomi Therapeutics, Inc. | $23.86M | $0.63 | — |
| ZIVO | Zivo Bioscience, Inc. | $23.18M | $5.50 | — |
News headlines (Yahoo Finance, 1h cache)
LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-16 21:05 · Yahoo
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
2026-09-03 11:00 · Yahoo
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances
2026-08-17 12:26 · Yahoo
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 20:05 · Yahoo
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
2026-08-12 11:00 · Yahoo
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
2026-06-04 11:00 · Yahoo
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-07 20:05 · Yahoo
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
2026-05-27 11:00 · Yahoo
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
2026-05-07 13:20 · Yahoo
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
2026-04-23 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.